Experimental CAR-T cell therapy for advanced B-cell cancer
Part of Blood & lymphatic clinical trials.
This trial tests a new type of immunotherapy where your own immune cells are collected, modified to recognize and attack cancer cells, and then returned to your body. It may be an option for people with B-cell cancers that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell cancer that carries CD19 or CD20 markers (like certain lymphomas or leukemias).
- Your cancer has returned or not responded to at least one previous treatment.
- You have at least one measurable spot of cancer on a PET scan or, for certain leukemias, cancer cells in blood or bone marrow.
- Your kidneys, liver, lungs, and heart are working well enough (for example, oxygen level at 92% or higher, and good kidney function).
- If you have had prior CAR-T therapy, your cancer must still show CD19 or CD20 markers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new type of CAR T-cell therapy that targets two markers (CD19 and CD20) on B-cell cancer cells. It is for people whose B-cell leukemia or lymphoma has come back or not responded to standard treatments.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.